Skip to content

Pharminent

cropped-ChatGPT-Image-Jun-22-2026-05_46_48-PM.png
Primary Menu
  • Home
  • Signal News
  • Biopharma Brief
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact
Light/Dark Button
Brief
  • Home
  • Commercial
  • Lilly’s Foundayo reaches 1,390 patients in first week, trailing Novo’s oral Wegovy launch
  • Commercial

Lilly’s Foundayo reaches 1,390 patients in first week, trailing Novo’s oral Wegovy launch

BioSpace

While Novo Nordisk's Wegovy pill reached more than 3,000 patients in its first week on the market, analysts at RBC Capital Markets said a direct comparison of the two figures could be misleading given

CommercialMetabolic & GLP-1Read full story

pharminent April 17, 2026 (Last updated: April 17, 2026)

BioSpace

While Novo Nordisk’s Wegovy pill reached more than 3,000 patients in its first week on the market, analysts at RBC Capital Markets said a direct comparison of the two figures could be misleading given

CommercialMetabolic & GLP-1Read full story

Sign up to receive free daily digest

Check your inbox or spam folder to confirm your subscription.

Post navigation

Previous: Obesity biotech Kailera’s record-breaking IPO
Next: Lilly’s obesity pill off to a strong start; OpenAI debuts new drug discovery tool

Related Stories

  • Commercial

Post-marketing oncology studies: Enabling faster recruitment and lower costs

pharminent June 22, 2026
  • Commercial

The first 14 days: How specialty programs set patients up for success

pharminent June 22, 2026
  • Commercial

Denali sells FDA voucher for $195M to support neurodegenerative pipeline

pharminent June 19, 2026

You May Have Missed

  • News

pharminent June 22, 2026
sample_feature_2026-06-22
  • News

AbbVie to Acquire Apogee Therapeutics for Nearly $11 Billion in Immunology Bet

pharminent June 22, 2026
  • M&A / Deals

AbbVie climbs post-Allergan M&A peak with Apogee buy

pharminent June 22, 2026
  • M&A / Deals

Lilly bets up to $800M for BioArctic’s brain delivery tech

pharminent June 22, 2026
© 2026 All rights reserved. | ReviewNews by AF themes.